1. Introduction {#sec1}
===============

Diabetes is an independent risk factor for coronary artery disease (CAD), and CAD is the main cause of death in diabetes patients. Compared to the nondiabetic population, diabetes is associated with a 2-3-fold increase in the risk of cardiovascular disease and mortality due to cardiovascular disease \[[@B1]\]. Diabetics without a history of myocardial infarction and nondiabetic patients with a history of myocardial infarction have approximately the same risks of acute myocardial infarction (AMI) and death from CAD \[[@B2]\]. Patients with diabetes tend to have more extensive, diffuse, calcified, and severe coronary artery lesions \[[@B3]\] and a higher Gensini score than nondiabetics \[[@B4]\]. AMI patients also have a high prevalence of diabetes, and the INTERHEART study, performed in 52 countries, indicated that diabetes contributed 10% of the attributable risk in newly diagnosed AMI patients \[[@B5]\]. The DECODE study indicated that abnormal glucose tolerance also increased the risk of cardiovascular disease and led to a poor prognosis \[[@B6]\]. Patients with an impaired fasting glucose (IFG) level and impaired glucose tolerance (IGT) have more severe coronary artery lesions \[[@B7]\]. Hyperglycemia is also an independent risk factor for both in-hospital and long-term poor prognosis in AMI patients \[[@B8]\]. Hyperglycemia is related to diabetic microvascular complications, including the incidence of diabetic retinopathy and diabetic nephropathy, the latter of which can be reduced by treating hyperglycemia \[[@B9]\]. This study examined the relationships between admission random blood glucose (RBG), fasting blood glucose (FBG), and Gensini score and evaluated the effects of RBG and FBG on the severity of CAD in AMI patients.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

A total of 958 consecutive AMI patients who underwent emergency coronary angiography at the Cardiology Department of Zhongda Hospital (affiliated with Southeast University), from January 1, 2016, to December 31, 2018, were enrolled in this study. The study population had an average age of 62.51 ± 13.49, and 744 (77.7%) were male. A total of 265 patients (27.7%) suffered stress hyperglycemia, and 589 (61.5%) had an elevated FBG level. Patients with AMI who underwent emergency coronary angiography and were aged 18--80 years were enrolled. The exclusion criteria were as follows: an allergy to iodine or iodine contrast agent, severe hemodynamic instability, severe liver and kidney dysfunction, severe infectious diseases, malignant tumors, severe blood system diseases, and incomplete data. All patients provided written informed consent before enrollment in the study.

2.2. Research Method {#sec2.2}
--------------------

Baseline data, including sex, age, height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), and Killip class, as well as previous and personal histories, including hypertension, diabetes, previous myocardial infarction (MI), cerebral infarction, chronic kidney dysfunction (CKD), and smoking history, were recorded. Hematological examination indexes, including RBG, FBG, troponin I (TNI), creatine kinase-muscle/brain (CK-MB), myoglobin (Myo), B-type natriuretic peptide (BNP), routine blood tests, liver and kidney function, serum lipids, echocardiography parameters, medications, coronary angiography data, and the use of an intra-aortic balloon pump (IABP) or coronary artery bypass grafting (CABG), were recorded.

### 2.2.1. Coronary Angiography {#sec2.2.1}

Left and right coronary angiographic examinations were performed via radial artery puncture; multiposition projection was performed according to Judkins\' method. The records were diagnosed independently by at least two interventional physicians blinded to the other data of the patients; a third physician performed the analysis when necessary.

### 2.2.2. Stress Hyperglycemia {#sec2.2.2}

The American Diabetes Association (ADA) defines stress hyperglycemia as an FBG level \>6.9 mmol/L or an RBG level \>11.1 mmol/L with no history of diabetes \[[@B10]\]. In this study, we defined an RBG \>11.1 mmol/L as stress hyperglycemia, regardless of the history of diabetes \[[@B10]\]. RBG was tested once patients entered hospital, and FBG was tested in the morning of the next day.

### 2.2.3. Gensini Score {#sec2.2.3}

The degree of stenosis and the coronary artery lesion site were scored as follows. The degree of stenosis score was multiplied by the lesion site score, and the sum of the lesion score was taken as the final Gensini score \[[@B11]\] ([Table 1](#tab1){ref-type="table"}). The Gensini score was defined by two separate doctors.

2.3. Statistical Analysis {#sec2.3}
-------------------------

SPSS 19.0 and MedCalc v18.11.3 software were used for all statistical analyses. Count data are expressed as cases and percentages, and the *χ*^2^ test was used for analysis. Numerical data are expressed as mean ± SD and were compared using the independent sample *t* test. Nonnormally distributed numerical data are expressed as the median and 25th--75th interquartile range and were compared using a rank-sum test. Spearman correlation analysis was used to evaluate the correlations between the RBG, FBG, and Gensini score. Multiple linear regression analysis and logistic regression analysis were performed to examine independent risk factors for Gensini score as continuous variables and hierarchical variables, respectively. In all analyses, *P* \< 0.05 was taken to indicate statistical significance.

3. Results {#sec3}
==========

3.1. Comparison of the Baseline Data, Hematological Indexes, Coronary Angiography Data, and Gensini Score in the Hyperglycemia Group and the Nonhyperglycemia Group {#sec3.1}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

There were significant differences in sex, age, hypertension, diabetes, previous MI, cerebral infarction, CKD, smoking, Killip class I, Killip class IV, BNP, white blood cell (WBC) count, alanine aminotransferase (ALT), RBG, estimated glomerular filtration rate (eGFR), FBG, triglycerides (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), left ventricular ejection fraction (LVEF), clopidogrel, ticagrelor, angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARBs), IABP, single-vessel lesion, double-vessel lesions, left main lesion, and Gensini score between the hyperglycemia group and the nonhyperglycemia group (*P* \< 0.05). There were no significant differences in height, weight, body mass index (BMI), SBP, DBP, Killip class II, Killip class III, TNI, Myo, CK-MB, hemoglobin (Hb), platelets (PLT), aspartate aminotransferase (AST), serum creatinine (Scr), uric acid (UA), aspirin, *β*-blocker, statin, calcium channel blocker (CCB), furosemide, antisterone, CABG, triple-vessel lesions, and number of stents between the hyperglycemia group and the nonhyperglycemia group (*P* \> 0.05) ([Table 2](#tab2){ref-type="table"}).

3.2. Comparison of Baseline Data, Hematological Parameters, Coronary Angiography Data, and Gensini Score in the FBG Elevated Group and the Non-FBG Elevated Group {#sec3.2}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

There were significant differences in sex, BMI, diabetes, cerebral infarction, smoking, Killip class I, Killip class IV, TNI, Myo, BNP, WBC, RBG, ALT, AST, FBG, HDL-C, LVEF, clopidogrel, ticagrelor, ACEI/ARB, furosemide, antisterone, IABP, single-vessel disease, triple-vessel disease, number of stents, left main lesion, and Gensini score between the elevated FBG group and the non-FBG elevated group (*P* \< 0.05). There were no significant differences in age, height, weight, SBP, DBP, hypertension, previous MI, CKD, Killip class II, Killip class III, CK-MB, Hb, PLT, Scr, eGFR, UA, TG, TC, LDL-C, aspirin, *β*-blocker, statin, CCB, CABG, or double-vessel disease (*P* \> 0.05) ([Table 3](#tab3){ref-type="table"}).

3.3. Correlation Analysis of RBG and FBG with Gensini Score in AMI Patients {#sec3.3}
---------------------------------------------------------------------------

Spearman correlation analysis showed a positive correlation between RBG and Gensini score (*r* = 0.182, *P* \< 0.001). In addition, there was a positive correlation between FBG and Gensini score (*r* = 0.171, *P* \< 0.001).

According to the quartile method, we divided the patients\' scores into four groups based on the Gensini score: group 1, Gensini score ≤ 37; group 2, 37 \< Gensini score ≤ 60; group 3, 60 \< Gensini score ≤ 88; and group 4, Gensini score \> 88. The correlation coefficient between the RBG and the Gensini score was highest in group 1 (*r* = 0.298, *P* \< 0.001).

3.4. Mean and Variance Analysis of RBG and FBG {#sec3.4}
----------------------------------------------

Both RBG and FBG increased with the increasing Gensini score. The mean values of the RBG in groups 1--4 were 9.08, 9.25, 10.19, and 10.83 mmol/L, respectively. In addition, the mean values of the FBG were 7.29, 7.64, 8.20, and 9.01 mmol/L, respectively ([Figure 1](#fig1){ref-type="fig"}).

A one-way analysis of variance showed significant differences in RBG and FBG between the different Gensini score groups. The least significant difference (LSD) test showed that the RBG was significantly higher in groups 3 and 4 than in group 1 (*P*=0.020 and *P* \< 0.001, respectively). Furthermore, the FBG was significantly higher in groups 3 and 4 than in group 1 (*P*=0.020 and *P* \< 0.001, respectively). The FBG was higher in group 4 than in groups 2 and 3 (*P*=0.001 and *P*=0.04) ([Table 4](#tab4){ref-type="table"}).

3.5. Multivariate Linear Regression Analysis {#sec3.5}
--------------------------------------------

After adjusting for age, BMI, hypertension, CKD, smoking history, and serum lipid level, multiple linear regression analysis of the Gensini score as a continuous variable showed that sex, diabetes, eGFR, and FBG were independent risk factors related to the Gensini score (*r* = 9.770, 8.366, −0.165, and 1.540, respectively; and *P*=0.015,  0.043,  0.044,  and 0.039, respectively). RBG was not an independent risk factor related to the Gensini score (*r* = 1.145 and *P*=0.112) ([Table 5](#tab5){ref-type="table"}).

Multiple logistic regression analysis showed that age and FBG were independent risk factors for the 37 \< Gensini score ≤ 60 group (*P*=0.001 and *P*=0.037, respectively) compared to the Gensini score ≤ 37 group. The eGFR and FBG were independent risk factors for the 60 \< Gensini score ≤ 88 group (*P*=0.014 and *P*=0.001, respectively). Furthermore, the eGFR and FBG were independent risk factors for the Gensini score \> 88 group (*P*=0.005 and *P* \< 0.001, respectively). Neither diabetes nor RBG was an independent risk factor for Gensini score ([Table 6](#tab6){ref-type="table"}).

4. Discussion {#sec4}
=============

This study explored the correlation between blood glucose and the severity of coronary lesions in AMI patients. Our research showed that 265 of 958 AMI patients had admission hyperglycemia, which accounted for 27.66% of all AMI patients. Besides, 589 patients had elevated FBG, nearly 1.6 times as many as patients with normal fasting blood glucose. Statistical analysis showed that FBG rather than RBG is an independent risk factor for the Gensini score. Multivariate linear regression analysis showed the regression coefficient for FBG to be 1.6.

The incidence rate of diabetes is increasing worldwide due to population aging, poor dietary patterns, and lack of exercise \[[@B12]\]. Diabetes mellitus is an important risk factor for cardiovascular disease, with diabetes mellitus patients showing a 2--4-fold higher risk of cardiovascular disease than people with normal blood glucose levels. More than 70% of diabetes patients over 65 die from cardiovascular and cerebrovascular diseases \[[@B13]\]. One-third of patients who undergo coronary intervention are diabetic, and a quarter of patients treated with CABG have a history of diabetes \[[@B14]\]. Coronary lesions tend to have greater inflammatory cell infiltration and more diffuse lesions in diabetic patients \[[@B15]\]. Diabetes is a risk factor for AMI, and diabetic patients with AMI have more severe lesions and an increased risk of poor short-term and long-term prognoses \[[@B16]\].

Stress hyperglycemia refers to transient hyperglycemia that occurs during the course of disease. The ADA defines stress hyperglycemia as an FBG level \>6.9 mmol/L or RBG level \>11.1 mmol/L without diabetes \[[@B10]\]. Stress hyperglycemia is closely related to mortality in AMI patients. In a meta-analysis involving 1856 AMI patients \[[@B8]\], the relative risk of in-hospital death in nondiabetic patients with stress hyperglycemia was 3.9-fold higher than that in patients with normal blood glucose levels (95% CI = 2.9--5.4), and diabetic patients with stress hyperglycemia were 1.7-fold more likely to die in hospital than those with normal blood glucose levels (95% CI = 1.2--2.4). Approximately half of all patients with ST-segment elevation MI (STEMI) are admitted with stress hyperglycemia \[[@B17]\], which can increase the MI area, severity of CAD, and mortality, leading to other adverse outcomes \[[@B18], [@B19]\]; decreased left ventricular systolic function may also be found \[[@B20]\]. The IABP-SHOCK II study showed that, in AMI patients with cardiogenic shock, RBG was an independent predictor of 30-day and 1-year mortality after MI. The 30-day mortality rates of patients with an RBG level ≥11.5 mmol/L and an RBG level \<11.5 mmol/L were 47.7% vs. 36.5%, respectively (*P* = 0.004), and the corresponding 1-year mortality rates were 57.7% vs. 47.1%, respectively (*P*=0.011) \[[@B21]\]. Among acute coronary syndrome patients, patients with stress hyperglycemia had a higher Gensini score, an increased incidence of 6-month major adverse cardiac events and an increased incidence of in-hospital arrhythmia \[[@B22]\]. RBG interferes with blood flow in the culprit vessel and is linearly correlated with the TIMI blood flow index \[[@B23]\]. Some studies have indicated that RBG on admission is closely related to mortality in nondiabetic patients \[[@B24]\].

AMI is a life-threatening acute disease, in the acute phase of the disease, the accumulation of oxidative stress, cytokines, catecholamines, cortisol, and inflammatory markers results in a decrease in gluconeogenesis and an acceleration of glycogen decomposition leading to hyperglycemia \[[@B25]\]. Hyperglycemia is also associated with endothelial barrier injury, activation of NF-kappa-b, impaired endothelium-dependent vascular diastolic function, and the overexpression of adhesion molecules such as intercellular adhesion molecules, vascular cell adhesion molecules, and e-selectin \[[@B26], [@B27]\]. Catecholamines, cortisol, and other hormones are also increased, leading to increased glucose utilization, which is conducive to cell hibernation and prevents further apoptosis in AMI patients \[[@B28]\]. Previous animal studies demonstrated that SGLT2 inhibition reduced the mortality of diabetic rats after MI through cardiac energy metabolism and the protective modification of antioxidant proteins, suggesting that hyperglycemia is related to a disturbance in energy metabolism and oxidative stress during AMI \[[@B29]\]. In patients with abnormal glucose tolerance and diabetes mellitus, catalase, superoxide dismutase, glutathione (GSH), GSH reductase, and GSH peroxidase were negatively correlated with the Gensini score, suggesting that oxidative stress is involved in the mechanism underlying the aggravation of CAD by hyperglycemia \[[@B30]\].

IFG refers to a fasting glucose level of 6.1--7.0 mmol/L. In a 5-year follow-up of newly diagnosed IFG patients at the Singapore National Hospital, 20 (0.9%) of the 2295 IFG patients developed AMI, which was significantly higher than the incidence in the normal blood glucose group \[[@B31]\]. In a prospective study, Uppalakal and Karanayil \[[@B32]\] reported a 40% incidence of metabolic syndrome in STEMI patients, 93% of whom had an elevated FBG level (FBG \> 100 mg). Elevated FBG is an independent risk factor for CAD (odds ratio (OR) = 2.238, 95% CI = 1.111--4.508, *P*=0.024); reducing FBG is beneficial for preventing the occurrence and reducing the incidence of CAD \[[@B33]\]. Elevated FBG is associated with the severity of CAD and is correlated with the Gensini score \[[@B34]\]. In a study of 1028 patients who underwent coronary angiography, patients with an elevated FBG level had more severe coronary artery lesions and higher Gensini scores (*P* \< 0.001). A meta-analysis \[[@B35]\] also indicated that IFG was an independent risk factor for cardiovascular disease (OR = 1.12--1.37). These results are consistent with those of the present study. However, some authors have reported the opposite findings; a follow-up study of 11338 patients indicated no significant difference in the severity of CAD and the incidence of composite cardiovascular endpoint events in patients with prediabetes compared to the normal population \[[@B36]\]. The FBG and postprandial blood glucose (PBG) were positively correlated with the Gensini score in 1852 patients who underwent coronary angiography (*r* = 0.09, *P* \< 0.01; and *r* = 0.20, *P* \< 0.01, respectively), whereas regression analysis showed that FBG rather than PBG was independently associated with Gensini score.

This study has several limitations. Firstly, this was a single-center study with a small sample size. A multicenter study with a larger sample size is needed to further evaluate the correlations between RBG, FBG, and Gensini score and to determine the predictive value for short-term and long-term adverse prognoses. Secondly, this study did not explore the correlation between PBG and Gensini score. Thirdly, we did not report the exact HbA1c value. Finally, this study did not clarify whether interventions for hyperglycemia can reverse its adverse effects.

5. Conclusions {#sec5}
==============

In conclusion, we should pay more attention to FBG, and timely intervention for hyperglycemia, by using insulin or other glucose-lowering medication, may bring more benefit for patients with myocardial infarction.

The research was funded by the National Natural Science Foundation of China (grant no. 81600227).

Data Availability
=================

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest
=====================

The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or nonfinancial interest in the subject matter or materials discussed in this manuscript.

![RBG and FBG mean distributions in different Gensini score groups.](BMRI2019-9707513.001){#fig1}

###### 

Gensini score rule.

  Degree of coronary artery stenosis   Score   Coronary lesion site   Score
  ------------------------------------ ------- ---------------------- -------
  ≤25%                                 1       LM                     5
  26%--50%                             2       Proximal LAD or LCX    2.5
  51%--75%                             4       Middle LAD             1.5
  76%--90%                             8       Distal LAD             1.0
  91%--99%                             16      Middle or distal LAD   1.0
  100%                                 32      RCA                    1.0
                                               Subbranch              0.5

LM: left main coronary artery; LAD: left anterior descending; LCX: left circumflex coronary; RCA: right coronary artery.

###### 

Comparison of baseline data, hematological indexes, coronary angiography data, and Gensini score between the hyperglycemia group and nonhyperglycemia group.

  Variables                                      Hyperglycemia group (*n* = 265)   Nonhyperglycemia group (*n* = 693)   *P* value
  ---------------------------------------------- --------------------------------- ------------------------------------ ---------------
  Sex (man)                                      193                               551                                  0.026^*∗*^
  Age                                            64.08 ± 12.94                     61.64 ± 13.47                        0.019^*∗*^
  Height (cm)                                    166.71 ± 7.44                     166.78 ± 7.54                        0.92
  Weight (kg)                                    68.55 ± 12.18                     68.76 ± 11.38                        0.844
  BMI (kg/m^2^)                                  24.93 ± 3.87                      24.44 ± 3.53                         0.132
  SBP (mmHg)                                     124.80 ± 24.80                    126.52 ± 20.83                       0.315
  DBP (mmHg)                                     76.14 ± 16.29                     76.98 ± 14.32                        0.472
  Hypertension                                   167                               384                                  0.033^*∗*^
  Diabetes                                       174                               88                                   \<0.001^*∗*^
  Previous MI                                    12                                10                                   0.013^*∗*^
  Cerebral infarction                            37                                65                                   0.040^*∗*^
  CKD                                            30                                49                                   0.032^*∗*^
  Smoking                                        119                               380                                  0.006^*∗*^
                                                                                                                        
  *Killip grade*                                                                                                         
  I grade                                        158                               502                                  \<0.001^*∗*^
  II grade                                       42                                112                                  0.906
  III grade                                      2                                 9                                    0.480
  IV grade                                       63                                70                                   \<0.001^*∗*^
  TNI P~50~ (P~25~--P~75~) (ng/ml)               17.9 (3.2--25)                    14 (3.53--25)                        0.286
  Myo P~50~ (P~25~--P~75~) (ng/ml)               500 (241--900)                    500 (239--900)                       0.096
  CK-MB P~50~ (P~25~--P~75~) (ng/ml)             80 (26.9--292)                    80 (44--303.25)                      0.406
  BNP P~50~ (P~25~--P~75~) (pg/ml)               216.5 (55.9--862)                 134 (43.3--393.25)                   0.002^*∗*^
  WBC (^*∗*^10^9^/L)                             12.46 ± 4.61                      11.19 ± 3.68                         \<0.001^*∗*^
  Hb (g/L)                                       133.21 ± 23.15                    135.99 ± 20.71                       0.098
  PLT (^*∗*^10^9^/L)                             207.48 ± 66.48                    204.68 ± 60.07                       0.564
  RBG (mmol/L)                                   16.34 ± 4.85                      7.35 ± 1.62                          \<0.001^*∗*^
  ALT P~50~ (P~25~--P~75~) (IU/L)                53 (34--82)                       44 (30--68.75)                       0.001^*∗*^
  AST P~50~ (P~25~--P~75~) (IU/L)                174.5 (79--323)                   157.5 (76.75--262.25)                0.073
  Scr P~50~ (P~25~--P~75~) (*μ*mol/L)            81 (71--105.5)                    80.5 (69--92)                        0.1
  eGFR P~50~ (P~25~--P~75~) (ml/min/1.73 m^2^)   77.18 (54.95--96.24)              82.37 (68.89--97.27)                 0.022^*∗*^
  UA(*μ*mol/L)                                   364.18 ± 143.79                   366.75 ± 115.43                      0.079
  FBG (mmoL/L)                                   12.00 ± 5.47                      6.45 ± 2.02                          \<0.001^*∗*^
  TG (mmoL/L)                                    2.12 ± 2.12                       1.67 ± 1.15                          0.004^*∗*^
  TC (mmoL/L)                                    4.27 ± 1.34                       4.48 ± 1.35                          0.044^*∗*^
  HDL-c (mmoL/L)                                 1.02 ± 0.25                       1.13 ± 0.41                          \<0.001^*∗*^
  LDL-c (mmoL/L)                                 2.62 ± 0.99                       2.80 ± 0.86                          0.017^*∗*^
  LVEF (%)                                       0.54 ± 0.12                       0.58 ± 0.11                          \<0.0010^*∗*^
  Aspirin                                        263                               681                                  0.26
  Clopidogrel                                    21                                95                                   0.014^*∗*^
  Ticagrelor                                     244                               598                                  0.014^*∗*^
  ACEI/ARB                                       112                               370                                  0.002^*∗*^
  *β*-blocker                                    214                               580                                  0.28
  Statin                                         265                               688                                  0.166
  CCB                                            16                                44                                   0.338
  Furosemide                                     72                                177                                  0.424
  Antisterone                                    70                                179                                  0.261
  IABP                                           28                                35                                   0.002^*∗*^
  CABG                                           5                                 8                                    0.381
                                                                                                                        
  *Coronary lesions*                                                                                                     
  Single-vessel lesion                           44                                192                                  \<0.001^*∗*^
  Double-vessel lesions                          95                                191                                  0.012^*∗*^
  Triple-vessel lesions                          126                               310                                  0.434
                                                                                                                        
  *Number of stents*                                                                                                     
  Single stent                                   167                               415                                  0.374
  Two or more stents                             44                                133                                  0.356
  Left main lesion                               37                                62                                   0.023^*∗*^
  Gensini score P~50~ (P~25~--P~75~)             71.5 (41--92)                     58 (36--87)                          0.006^*∗*^

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; CKD: chronic kidney diseases; TNI: troponin; Myo: myohemoglobin; CK-MB: creatine kinase-MB; BNP: brain natriuretic peptide; WBC: white blood cell; Hb: hemoglobin; PLT: platelet; RBG: random blood glucose; ALT: alanine transaminase; AST: Aspartate transaminase; Scr: serum creatinine; eGFR: estimated glomerular filtration rate; UA: uric acid; FBG: fasting blood glucose; TG: triglyceride; TC: total cholesterol; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol; LVEF: left ventricular ejection fraction; CCB: calcium channel blocker; IABP: intra-aortic balloon pump; CABG: coronary artery bypass grafting.

###### 

Comparison of baseline data, hematological parameters, coronary angiography data, and Gensini score between the FBG elevated group and the non-FBG elevated group.

  Variables                                      FBG elevated group (*n* = 589)   Non-FBG elevated group (*n* = 369)   *P* value
  ---------------------------------------------- -------------------------------- ------------------------------------ --------------
  Sex (man)                                      433                              303                                  0.002^*∗*^
  Age                                            62.91 ± 13.01                    61.72 ± 13.84                        0.185
  Height (cm)                                    166.77 ± 7.64                    166.70 ± 7.20                        0.087
  Weight (kg)                                    69.02 ± 12.20                    68.15 ± 11.73                        0.319
  BMI (kg/m^2^)                                  24.77 ± 3.70                     24.09 ± 3.71                         0.012^*∗*^
  SBP (mmHg)                                     127.08 ± 23.18                   125.34 ± 19.14                       0.235
  DBP (mmHg)                                     76.89 ± 15.05                    76.44 ± 13.84                        0.467
  Hypertension                                   349                              202                                  0.169
  Diabetes                                       242                              20                                   \<0.001^*∗*^
  Previous MI                                    15                               7                                    0.514
  Cerebral infarction                            86                               16                                   \<0.001^*∗*^
  CKD                                            54                               25                                   0.190
  Smoking                                        283                              216                                  0.002^*∗*^
                                                                                                                       
  *Killip grade*                                                                                                        
  I grade                                        367                              293                                  \<0.001^*∗*^
  II grade                                       103                              51                                   0.133
  III grade                                      9                                2                                    0.163
  IV grade                                       99                               34                                   \<0.001^*∗*^
                                                                                                                       
  TNI P~50~ (P~25~--P~75~) (ng/ml)               17 (3.98--25)                    11 (2.3--25)                         0.002^*∗*^
  Myo P~50~ (P~25~--P~75~) (ng/ml)               500 (219.75--900)                500 (206.25--900)                    0.016^*∗*^
  CK-MB P~50~ (P~25~--P~75~) (ng/ml)             80 (36.45--297)                  80 (37.5--246.5)                     0.260
  BNP P~50~ (P~25~--P~75~) (pg/ml)               173 (49.75--587.5)               112 (41.45--347.5)                   0.001^*∗*^
  WBC (^*∗*^10^9^/L)                             12.29 ± 4.45                     10.47 ± 2.94                         \<0.001^*∗*^
  Hb (g/L)                                       134.5 ± 23.11                    135.99 ± 20.71                       0.066
  PLT (^*∗*^10^9^/L)                             209.87 ± 63.42                   201.7 ± 58.36                        0.051
  RBG (mmol/L)                                   11.25 ± 5.21                     7.22 ± 2.35                          \<0.001^*∗*^
  ALT P~50~ (P~25~--P~75~) (IU/L)                48 (33--79)                      39 (29--59)                          \<0.001^*∗*^
  AST P~50~ (P~25~--P~75~) (IU/L)                145 (60--219)                    171 (89--309)                        \<0.001^*∗*^
  Scr P~50~ (P~25~--P~75~) (*μ*mol/L)            81 (67--98)                      80 (72--91)                          0.862
  eGFR P~50~ (P~25~--P~75~) (ml/min/1.73 m^2^)   80.91 (62.22--97.88)             81.56 (69.16--96.16)                 0.704
  UA(*μ*mol/L)                                   376.41 ± 143.79                  365.35 ± 122.55                      0.152
  FBG (mmoL/L)                                   9.79 ± 4.67                      5.22 ± 0.52                          \<0.001^*∗*^
  TG (mmoL/L)                                    1.83 ± 1.66                      1.64 ± 0.98                          0.051
  TC (mmoL/L)                                    4.46 ± 1.34                      4.42 ± 0.98                          0.667
  HDL-c (mmoL/L)                                 1.12 ± 0.44                      1.07 ± 0.30                          0.046^*∗*^
  LDL-c (mmoL/L)                                 2.77 ± 0.99                      2.80 ± 0.82                          0.682
  LVEF (%)                                       0.53 ± 0.38                      0.68 ± 0.34                          \<0.001^*∗*^
  Aspirin                                        581                              364                                  0.997
  Clopidogrel                                    61                               55                                   0.028^*∗*^
  Ticagrelor                                     528                              314                                  0.028^*∗*^
  ACEI/ARB                                       277                              205                                  0.01^*∗*^
  *β*-blocker                                    494                              300                                  0.304
  Statin                                         586                              367                                  0.946
  CCB                                            30                               30                                   0.059
  Furosemide                                     174                              75                                   0.002^*∗*^
  Antisterone                                    172                              77                                   0.004^*∗*^
  IABP                                           51                               12                                   0.001^*∗*^
  CABG                                           10                               3                                    0.249
                                                                                                                       
  *Coronary lesions*                                                                                                    
  Single-vessel lesion                           101                              135                                  \<0.001^*∗*^
  Double-vessel lesions                          171                              115                                  0.483
  Triple-vessel lesions                          284                              152                                  0.034^*∗*^
                                                                                                                       
  *Number of stents*                                                                                                    
  Single stent                                   340                              242                                  0.015^*∗*^
  Two or more stents                             124                              53                                   0.009^*∗*^
  Left main lesion                               75                               24                                   0.002^*∗*^
  Gensini score P~50~ (P~25~--P~75~)             65 (42--92)                      52 (32--82)                          \<0.001^*∗*^

SBP: systolic blood pressure; DBP: diastolic blood pressure; CKD: chronic kidney diseases; TNI: troponin; Myo: myohemoglobin; CK-MB: creatine kinase-MB; BNP: brain natriuretic peptide; WBC: white blood cell; Hb: hemoglobin; PLT: platelet; RBG: random blood glucose; ALT: alanine transaminase; AST: aspartate transaminase; Scr: serum creatinine; eGFR: estimated glomerular filtration rate; UA: uric acid; FBG: fasting blood glucose; TG: triglyceride; TC: total cholesterol; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol; LVEF: left ventricular ejection fraction; CCB: calcium channel blocker; IABP: intra-aortic balloon pump; CABG: coronary artery bypass grafting.

###### 

RBG and FBG in different Gensini score groups by the LSD method.

      RBG   FBG                                                            
  --- ----- ------- ------- ------- -------------- ------- ------- ------- --------------
  1   2     −0.17   −0.13   0.79    0.733          −0.35   −1.12   0.42    0.378
      3     −1.11   −2.05   −0.17   0.020^*∗*^     −0.91   −1.67   −0.14   0.020^*∗*^
      4     −1.75   −2.71   −0.80   \<0.001^*∗*^   −1.72   −2.5    −0.94   \<0.001^*∗*^
  2   3     −0.94   −1.89   0.01    0.051          −0.56   −1.33   0.21    0.152
      4     −1.59   −2.59   −0.62   0.001^*∗*^     −1.37   −2.15   −0.59   0.001^*∗*^
  3   4     −0.64   −1.59   0.30    0.183          −0.81   −1.59   −0.04   0.04^*∗*^

RBG: random blood glucose; FBG: fasting blood glucose. ^*∗*^*P* \< 0.05.

###### 

Multivariate linear regression analysis for Gensini score as a continuous variable.

  Variables      *β*      *P* value
  -------------- -------- ------------
  Sex            9.770    0.015^*∗*^
  Age            0.125    0.098
  BMI            0.05     0.793
  Hypertension   1.147    0.701
  Diabetes       8.366    0.043^*∗*^
  CKD            0.508    0.936
  Smoking        2.453    0.467
  eGFR           −0.165   0.044^*∗*^
  FBG            1.540    0.039^*∗*^
  RBG            1.145    0.112
  TG             0.409    0.138
  TC             2.254    0.252
  HDL-c          0.465    0.372
  LDL-c          −0.503   0.636

CKD: chronic kidney diseases; eGFR: estimated glomerular filtration rate; RBG: random blood glucose; FBG: fasting blood glucose; TG: triglyceride; TC: total cholesterol; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol.

###### 

Multivariate logistic regression analysis for the Gensini score as a hierarchical variable.

  Gensini score group        Variables   OR             95% CI         *P* value
  -------------------------- ----------- -------------- -------------- -----------
  *Gensini score* *≤* 37                                                
  37 \< Gensini score ≤ 60   Sex         1.20           0.729--1.974   0.473
  Age                        1.031       1.013--1.050   0.001^*∗*^     
  Diabetes                   1.001       0.513--1.812   0.997          
  eGFR                       1.006       0.000--1.014   0.090          
  RBG                        0.941       0.878--1.009   0.087          
  FBG                        1.111       1.006--1.226   0.037^*∗*^     
  60 \< Gensini score ≤ 88   Sex         1.233          0.746--2.039   0.414
  Age                        0.99        0.973--1.007   0.260          
  Diabetes                   0.949       0.573--1.679   0.858          
  eGFR                       0.99        0.983--0.998   0.014^*∗*^     
  RBG                        0.959       0.901--1.002   0.199          
  FBG                        1.067       1.006--1.279   0.001^*∗*^     
  Gensini score \> 88        Sex         0.688          0.400--1.182   0.176
  Age                        1.018       0.999--1.037   0.057          
  Diabetes                   0.615       0.337--1.120   0.112          
  eGFR                       0.988       0.980--0.996   0.005^*∗*^     
  RBG                        0.986       0.926--1.050   0.667          
  FBG                        1.202       1.097--1.316   \<0.001^*∗*^   

eGFR: estimated glomerular filtration rate; RBG: random blood glucose; FBG: fasting blood glucose. ^*∗*^*P* \< 0.05.

[^1]: Academic Editor: Lei Ye
